Abstract:Non-alcoholic fatty liver disease (NAFLD) has become a major chronic disease in contemporary society, affected by N6-methyladenosine (m6A) RNA methylation, one of the most common RNA modifications. Compared with healthy control, m6A RNA methyltransferase 3 (METTL3) and METTL14 increased, while Wilms tumor 1-associated protein (WTAP) and RNA-binding motif protein 15 (RBM15) decreased significantly in NAFLD, and the m6A demethylases fat mass and obesity-associated protein (FTO) elevated. Meanwhile, the m6A binding proteins, YT521-B homology (YTH) domain-containing 1 (YTHDC1), YTHDC2, insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1), heterogeneous nuclear ribonucleoprotein C (HNRNPC), and HNRNPA2B1 were decreased, while eukaryotic translation initiation factor 3 subunit H (EIF3H) was increased significantly. All these changes of m6A regulators had significant differences between healthy control and NAFLD, but no differences between the NAFL and NASH group. The expression level of RBM15, HNRNPC, and HNRNPA2B1 were related to body fat index. RBM15, YTHDC2, HNRNPC, HNRNPA2B1, and EIF3H were related to steatosis. Also, KIAA1429 and YTH domain family 1 (YTHDF1) were related to lobular inflammation. Taken together, m6A regulators were involved in the occurrence of NAFLD. More importantly, abnormal MYC was determined as a key link to m6A regulation of NAFLD. The higher MYC mRNA level was accompanied by higher HDL cholesterol and unsaturated fatty acid proportions, as well as lower fat mass, glucose, and transaminase. Taken together, dysregulation of m6A methylation caused steatosis and fibrosis, affecting the occurrence of NAFLD, and MYC might be its potential target.

The role of N6-methyladenosine in macrophage polarization: A novel treatment strategy for non-alcoholic steatohepatitis

The emerging roles of N6-methyladenosine RNA methylation in human cancers

N6-methyladenosine RNA methylation in liver diseases: from mechanism to treatment

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

Novel insights into macrophage immunometabolism in nonalcoholic steatohepatitis

The role of N6-methyladenosine modification in the life cycle and disease pathogenesis of hepatitis B and C viruses

RNA modifications in the progression of liver diseases: from fatty liver to cancer

The Roles of M6a RNA Modifiers in Human Cancer

Potential applications of N6 -methyladenosine modification in the prognosis and treatment of cancers via modulating apoptosis, autophagy, and ferroptosis

N6-Methyladenosine (m6A) Modification in Natural Immune Cell-Mediated Inflammatory Diseases

Roles of N6‐methyladenosine epitranscriptome in non‐alcoholic fatty liver disease and hepatocellular carcinoma

New roles of N6-methyladenosine methylation system regulating the occurrence of non-alcoholic fatty liver disease with N6-methyladenosine-modified MYC

New horizons for the role of RNA N6-methyladenosine modification in hepatocellular carcinoma

Insights into RNA N6-methyladenosine in Glucose and Lipid Metabolic Diseases and Their Therapeutic Strategies

Potential applications of <i>N</i><SUP>6</SUP>-methyladenosine modification in the prognosis and treatment of cancers via modulating apoptosis, autophagy, and ferroptosis

Potential Roles of N6-methyladenosine (m6a) in Immune Cells

RNA m6A Modification in Immunocytes and DNA Repair: The Biological Functions and Prospects in Clinical Application

N 6 ‐methyladenosine Steers RNA Metabolism and Regulation in Cancer

Mechanisms of RNA N 6 -Methyladenosine in Hepatocellular Carcinoma: From the Perspectives of Etiology.

Role of N6-methyladenosine RNA modification in cancer

N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy